FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 346:642 February 28, 2002 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Reid, I. R. PubMed Citation

Osteoporosis affects millions of postmenopausal women in the United States alone. For white women who reach 50 years of age, the lifetime risk of vertebral fracture is about one in three, and that for hip fracture is one in six. One tenth to one fifth of the women who have a hip fracture die within a year after it occurs, and one quarter must move permanently to a nursing home.

Although potentially devastating, osteoporotic fractures can be prevented. Adequate calcium intake (at least 1200 mg daily for postmenopausal women) and vitamin D intake (400 to 800 IU daily) and regular . . . [Full Text of this Article]

This article has been cited by other articles:

• Klion, A. D., Robyn, J., Maric, I., Fu, W., Schmid, L., Lemery, S., Noel, P., Law, M. A., Hartsell, M., Talar-Williams, C., Fay, M. P., Dunbar, C. E., Nutman, T. B. (2007). Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 110: 3552-3556 [Abstract] [Full Text]  
• Gold, D. T, Alexander, I. M, Ettinger, M. P (2006). How Can Osteoporosis Patients Benefit More from Their Therapy? Adherence Issues with Bisphosphonate Therapy. The Annals of Pharmacotherapy 40: 1143-1150 [Abstract] [Full Text]  
• Tauchmanova, L., Ricci, P., Serio, B., Lombardi, G., Colao, A., Rotoli, B., Selleri, C. (2005). Short-Term Zoledronic Acid Treatment Increases Bone Mineral Density and Marrow Clonogenic Fibroblast Progenitors after Allogeneic Stem Cell Transplantation. J. Clin. Endocrinol. Metab. 90: 627-634 [Abstract] [Full Text]  
• Klion, A. D., Robyn, J., Akin, C., Noel, P., Brown, M., Law, M., Metcalfe, D. D., Dunbar, C., Nutman, T. B. (2004). Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103: 473-478 [Abstract] [Full Text]